Stephen Nava
Corporate Officer/Principal at Regulator Affairs Quality Assurance Consulting Services, Inc.
Stephen Nava active positions
| Companies | Position | Start | End |
|---|---|---|---|
| Regulator Affairs Quality Assurance Consulting Services, Inc. | Corporate Officer/Principal | 01/01/2004 | - |
Career history of Stephen Nava
Former positions of Stephen Nava
| Companies | Position | Start | End |
|---|---|---|---|
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | General Counsel | 01/01/2005 | 01/06/2011 |
| Acumen Sciences LLC | General Counsel | 01/01/2002 | 01/01/2004 |
| VIRACTA THERAPEUTICS, INC. | Compliance Officer | 09/07/2018 | - |
| General Counsel | 09/07/2018 | - |
Training of Stephen Nava
| Texas A&M University-Kingsville | Undergraduate Degree |
Statistics
International
| United States | 6 |
Operational
| General Counsel | 3 |
| Compliance Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 4 |
|---|---|
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
BiPar Sciences, Inc.
BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology BiPar Sciences, Inc. develops and markets drugs for cancer patients. It offers BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor for metastatic triple negative breast cancer, ovarian cancer, and other malignancies; BSI-401, a follow-on PARP inhibitor candidate for pancreatic cancer; and BSI-301, an iodothyronine program with anti-tubulin properties. The company was founded by Barry M. Sherman, Thomas F. White and Allan Basbaum in 2002 and is headquartered in Bridgewater, NJ. | Health Technology |
| Acumen Sciences LLC | |
| Regulator Affairs Quality Assurance Consulting Services, Inc. |
- Stock Market
- Insiders
- Stephen Nava
- Experience
